Report cover image

Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 200 Pages
SKU # APRC20556385

Description

Summary

According to APO Research, the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market include Abbott, Takeda, Fresenius, Amgen, Abbvie, Vifor, Spectrum, Shield and Sanofi Genzyme, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD), also provides the sales of main regions and countries. Of the upcoming market potential for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) sales, projected growth trends, production technology, application and end-user industry.

Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Company

Abbott
Takeda
Fresenius
Amgen
Abbvie
Vifor
Spectrum
Shield
Sanofi Genzyme
OPKO
Novadiol
Japan Tobacco Company
Daiichi-Sankyo
Astellas
Ardelyx
Akebia
Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Type

Maintain Blood Calcium Levels
Control Hyperphosphatemia
Control PTH Level
Correct Acidosis
Others
Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Application

Hospital Pharmacies
Drug Stores
Online Pharmacies
Retail Pharmacies
Others
Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) significant trends, drivers, influence factors in global and regions.
6. To analyze Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) industry.
Chapter 3: Detailed analysis of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

200 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2020-2031)
1.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume (2020-2031)
1.2.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Dynamics
2.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Trends
2.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Drivers
2.3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Opportunities and Challenges
2.4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Industry Restraints
3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Company
3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Revenue Ranking in 2024
3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Revenue by Company (2020-2025)
3.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Company (2020-2025)
3.4 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Average Price by Company (2020-2025)
3.5 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Ranking (2023-2025)
3.6 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Manufacturing Base and Headquarters
3.7 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Product Type and Application
3.8 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Type
4.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Type Introduction
4.1.1 Maintain Blood Calcium Levels
4.1.2 Control Hyperphosphatemia
4.1.3 Control PTH Level
4.1.4 Correct Acidosis
4.1.5 Others
4.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type
4.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Type (2020-2031)
4.2.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Type (2020-2031)
4.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type
4.3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Type (2020-2031)
4.3.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type (2020-2031)
5 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market by Application
5.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Application Introduction
5.1.1 Hospital Pharmacies
5.1.2 Drug Stores
5.1.3 Online Pharmacies
5.1.4 Retail Pharmacies
5.1.5 Others
5.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application
5.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume by Application (2020-2031)
5.2.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Volume Share by Application (2020-2031)
5.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application
5.3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Application (2020-2031)
5.3.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application (2020-2031)
6 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Regional Sales and Value Analysis
6.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region (2020-2031)
6.2.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region: 2020-2025
6.2.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Region (2026-2031)
6.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region (2020-2031)
6.4.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region: 2020-2025
6.4.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Region (2026-2031)
6.5 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2020-2031)
6.6.2 North America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2020-2031)
6.7.2 Europe Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2020-2031)
6.8.2 Asia-Pacific Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2020-2031)
6.9.2 South America Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value (2020-2031)
6.10.2 Middle East & Africa Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Country, 2024 VS 2031
7 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Country-level Sales and Value Analysis
7.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2020-2031)
7.3.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2020-2025)
7.3.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales by Country (2026-2031)
7.4 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2020-2031)
7.4.1 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2020-2025)
7.4.2 Global Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.5.2 USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.6.2 Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.8.2 Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.9.2 France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.9.3 France Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.11.2 Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.12.2 Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.13.2 Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.16.2 China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.16.3 China Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.17.2 Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.19.2 India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.19.3 India Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.20.2 Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.24.2 Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.26.2 Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.28.2 Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.29.2 UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.31.2 Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Abbott
8.1.1 Abbott Comapny Information
8.1.2 Abbott Business Overview
8.1.3 Abbott Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.1.4 Abbott Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.1.5 Abbott Recent Developments
8.2 Takeda
8.2.1 Takeda Comapny Information
8.2.2 Takeda Business Overview
8.2.3 Takeda Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.2.4 Takeda Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.2.5 Takeda Recent Developments
8.3 Fresenius
8.3.1 Fresenius Comapny Information
8.3.2 Fresenius Business Overview
8.3.3 Fresenius Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.3.4 Fresenius Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.3.5 Fresenius Recent Developments
8.4 Amgen
8.4.1 Amgen Comapny Information
8.4.2 Amgen Business Overview
8.4.3 Amgen Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.4.4 Amgen Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.4.5 Amgen Recent Developments
8.5 Abbvie
8.5.1 Abbvie Comapny Information
8.5.2 Abbvie Business Overview
8.5.3 Abbvie Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.5.4 Abbvie Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.5.5 Abbvie Recent Developments
8.6 Vifor
8.6.1 Vifor Comapny Information
8.6.2 Vifor Business Overview
8.6.3 Vifor Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.6.4 Vifor Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.6.5 Vifor Recent Developments
8.7 Spectrum
8.7.1 Spectrum Comapny Information
8.7.2 Spectrum Business Overview
8.7.3 Spectrum Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.7.4 Spectrum Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.7.5 Spectrum Recent Developments
8.8 Shield
8.8.1 Shield Comapny Information
8.8.2 Shield Business Overview
8.8.3 Shield Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.8.4 Shield Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.8.5 Shield Recent Developments
8.9 Sanofi Genzyme
8.9.1 Sanofi Genzyme Comapny Information
8.9.2 Sanofi Genzyme Business Overview
8.9.3 Sanofi Genzyme Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.9.4 Sanofi Genzyme Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.9.5 Sanofi Genzyme Recent Developments
8.10 OPKO
8.10.1 OPKO Comapny Information
8.10.2 OPKO Business Overview
8.10.3 OPKO Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.10.4 OPKO Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.10.5 OPKO Recent Developments
8.11 Novadiol
8.11.1 Novadiol Comapny Information
8.11.2 Novadiol Business Overview
8.11.3 Novadiol Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.11.4 Novadiol Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.11.5 Novadiol Recent Developments
8.12 Japan Tobacco Company
8.12.1 Japan Tobacco Company Comapny Information
8.12.2 Japan Tobacco Company Business Overview
8.12.3 Japan Tobacco Company Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.12.4 Japan Tobacco Company Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.12.5 Japan Tobacco Company Recent Developments
8.13 Daiichi-Sankyo
8.13.1 Daiichi-Sankyo Comapny Information
8.13.2 Daiichi-Sankyo Business Overview
8.13.3 Daiichi-Sankyo Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.13.4 Daiichi-Sankyo Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.13.5 Daiichi-Sankyo Recent Developments
8.14 Astellas
8.14.1 Astellas Comapny Information
8.14.2 Astellas Business Overview
8.14.3 Astellas Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.14.4 Astellas Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.14.5 Astellas Recent Developments
8.15 Ardelyx
8.15.1 Ardelyx Comapny Information
8.15.2 Ardelyx Business Overview
8.15.3 Ardelyx Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.15.4 Ardelyx Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.15.5 Ardelyx Recent Developments
8.16 Akebia
8.16.1 Akebia Comapny Information
8.16.2 Akebia Business Overview
8.16.3 Akebia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales, Value and Gross Margin (2020-2025)
8.16.4 Akebia Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Product Portfolio
8.16.5 Akebia Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Value Chain Analysis
9.1.1 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Mode & Process
9.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Distributors
9.2.3 Chronic Kidney Disease–Mineral and Bone Disorders (CKD-MBD) Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.